Chinese herbal granules for relapsing-remitting multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a traditional Chinese medicine (Yishen Daluo Yin granules) for people with relapsing-remitting multiple sclerosis (MS), the most common form where symptoms come and go. The goal is to see if this herbal treatment can reduce relapses and is safe to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You have been diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- You have had at least one relapse in the past two years, or a recent MRI showing active disease.
- Your disability level is mild to moderate (EDSS score between 0 and 5.5).
- You have not had a relapse in the last 30 days and your symptoms are stable.
- You are not currently taking certain other MS treatments (like steroids, interferons, or other immune-modulating drugs) within the last month, and some stronger treatments must have been stopped earlier.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a traditional Chinese herbal formula to standard multiple sclerosis (MS) treatments helps reduce MS activity. It aims to see if the combination is more effective than medication alone.
This study tests an experimental oral drug, PRO-1562, in two parts: first in healthy volunteers to check safety, then in people with relapsing multiple sclerosis to see if it can reduce disease activity. It may offer a new, convenient treatment option.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This study tests whether adding a probiotic supplement to your usual MS treatment (or to no treatment) can help manage relapsing-remitting multiple sclerosis. It aims to see if the probiotic is safe and beneficial as an add-on therapy.
This study tests an oral medication, dimethyl fumarate, which is already used for multiple sclerosis. It aims to see how well it controls relapses in people with relapsing forms of MS. If you have had a relapse in the last year, you might be eligible.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
Hear when a new Relapse Remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.